This is a multicentre, non-interventional, single arm study that aims to describe the treatment patterns in France: patients' characteristics, disease characteristics, prior treatments for Severe chronic rhinosinusitis with nasal polyposis and treatment prescription modalities. As well as to assess the clinical outcome after initiation of dupilumab (Dupixent®) and safety of the product during the two years of treatment
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Patient characteristics: Age
Timeframe: At baseline (Day 1)
Patient characteristics: Sex
Timeframe: At baseline (Day 1)
Patient characteristics: Weight
Timeframe: At baseline (Day 1)
Patient characteristics: Height
Timeframe: At baseline (Day 1)
Patient characteristics: Type 2 comorbidities
Timeframe: At baseline (Day 1)
Patient characteristics: Medical history
Timeframe: At baseline (Day 1)
Patient characteristics: Lifestyle habits
Timeframe: At baseline (Day 1)
Disease characteristics: CRSwNP duration
Timeframe: At baseline (Day 1)
Disease characteristics: Age at diagnosis of CRSwNP
Timeframe: At baseline (Day 1)
Disease characteristics: Blood Eosinophils
Timeframe: At baseline (Day 1)
Disease characteristics: Total serum IgE
Timeframe: At baseline (Day 1)
Disease characteristics: Anatomopathology
Timeframe: At baseline (Day 1)
Disease characteristics: Nasal polyps score (NPS) at baseline
Timeframe: At baseline (Day 1)
Disease characteristics: Nasal congestion score (NCS) at baseline
Timeframe: At baseline (Day 1)
Disease characteristics: Rhinorrhea score (anterior/posterior) at baseline
Timeframe: At baseline (Day 1)
Disease characteristics: VAS for CRSwNP symptoms at baseline
Timeframe: At baseline (Day 1)
Disease characteristics: smell test score Visual Analog Scale (VAS) at baseline
Timeframe: At baseline (Day 1)
Concomitant and prior medications for CRSwNP or other disease: Number of patients with at least one prior or concomitant SCS
Timeframe: From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease:Type of prior Systemic Corticosteroids (SCS) per patient
Timeframe: From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease: Cumulative dose of SCS
Timeframe: From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease: Total number of SCS bursts per patient
Timeframe: From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease: Recovery of sense of smell after SCS
Timeframe: From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease:Time since the most recent SCS burst before initiation of Dupixent®
Timeframe: From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease: Number of prior or respiratory concomitant biotherapies per patient
Timeframe: From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other diseases: Indication
Timeframe: From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other diseases: Reason for stop
Timeframe: From baseline up to 24 months.
Dupilumab (Dupixent®) modalities: Dosage
Timeframe: From baseline up to 24 months.
Dupilumab (Dupixent®) modalities: Injection modalities
Timeframe: From baseline up to 24 months.
Dupilumab (Dupixent®) modalities: Treatment duration
Timeframe: From baseline up to 24 months.
Dupilumab (Dupixent®) modalities: Compliance with treatment
Timeframe: From baseline up to 24 months.